Datapoint: FDA Rejects Fasenra for Nasal Polyps

The FDA last week rejected AstraZeneca’s application to expand its IL-5 inhibitor Fasenra into chronic rhinosinusitis with nasal polyps. The injectable is currently approved to treat asthma, where it holds covered or better status for 78% of all insured lives under the pharmacy benefit. 32.9% of covered lives have preferred access to Fasenra, largely with utilization management restrictions.

SOURCE: MMIT Analytics, as of 3/21/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: Dupixent Scores First-in-Class EoE Nod

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: HealthPartners to Launch Insurance Products With Avera

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 19

Datapoint: Lilly Scores Diabetes, Obesity Nods for Mounjaro

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today